Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: A system for controlling building services, the system including a services array supporting a plurality of service devices, an electronic controller that communicates with a client device to determine a selected profile defining service device settings and control the service devices in the services array in accordance with the service device settings defined by the profile, to thereby at least partially control building services.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: A method, non-transitory computer readable medium and storage server computing device that determines when a generated storage operation corresponds with one of a set of predefined storage operations. The storage operation is executed and a result of the execution of the storage operation is withheld from a file system, when the determining indicates that the storage operation corresponds with one of the set of predefined storage operations. A determination is made when a consistency point operation has completed. The result of the execution of the storage operation is presented to the file system, when the determining indicates that a consistency point operation has completed. This technology reduces the number of storage operations that are required to be journaled to maintain consistency of a file system, thereby reducing the runtime resources required to facilitate the journaling and replay resource required to replay the storage operations in a journal following a recovery.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: A method, non-transitory computer readable medium, and device that assists with dynamic resource reservation based on classified input/output requests includes receiving an input/output request from a client computing device. The input/output request is classified as a first priority request, wherein the first priority request has priority to a second priority request. A deadline time period to execute the received input/output request classified as the first priority request is determined and the first priority request is added to a first priority queue. The first priority request in the first priority queue is processed by assigning a plurality of reserved resources.

Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Abstract: Methods and systems for inter-cluster storage system monitoring and analysis are provided. The method includes monitoring a non-volatile memory delay center for a first storage cluster having a first node and a second node configured to operate as a first high availability pair, where data for a write request to write data to the first node is also written to the second node as well as to a second cluster having a third node and a fourth node, where the third node and the fourth node are also configured to operate as a second high availability pair to store the data for the write request at one or both of the third and fourth node. The non-volatile memory delay center is used to monitor and detect latency due to any delay caused by a non-volatile memory of the first node used as a write cache.

Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: Methods and systems for inter-cluster storage system monitoring and analysis are provided. The method includes monitoring a non-volatile memory delay center for a first storage cluster having a first node and a second node configured to operate as a first high availability pair, where data for a write request to write data to the first node is also written to the second node as well as to a second cluster having a third node and a fourth node, where the third node and the fourth node are also configured to operate as a second high availability pair to store the data for the write request at one or both of the third and fourth node. The non-volatile memory delay center is used to monitor and detect latency due to any delay caused by a non-volatile memory of the first node used as a write cache.

Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).

Abstract: The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).

Abstract: The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.